Correll CU, Schooler NR (2020) Negative symptoms in schizophrenia: a review and clinical guide for recognition, assessment, and treatment. Neuropsychiatr Dis Treat 16:519–534

Article  PubMed  PubMed Central  Google Scholar 

Kahn RS et al (2015) Schizophrenia. Nat Rev Dis Prim 1:15067

Article  PubMed  Google Scholar 

Millan MJ et al (2016) Altering the course of schizophrenia: progress and perspectives. Nat Rev Drug Discov 15:485–515

Article  CAS  PubMed  Google Scholar 

Global, regional, and national incidence, prevalence, and years lived with disability for 354 diseases and injuries for 195 countries and territories, 1990-2017: a systematic analysis for the Global Burden of Disease Study 2017 (2018) GBD 2017 Disease and Injury Incidence and Prevalence Collaborators. Lancet 392:1789–1858

Huhn M et al (2019) Comparative efficacy and tolerability of 32 oral antipsychotics for the acute treatment of adults with multi-episode schizophrenia: a systematic review and network meta-analysis. Lancet 394:939–951

Article  CAS  PubMed  PubMed Central  Google Scholar 

Kishimoto T, Hagi K, Nitta M, Kane JM, Correll CU (2019) Long-term effectiveness of oral second-generation antipsychotics in patients with schizophrenia and related disorders: a systematic review and meta-analysis of direct head-to-head comparisons. World Psychiatry 18:208–224

Article  PubMed  PubMed Central  Google Scholar 

Leucht S et al (2012) Antipsychotic drugs versus placebo for relapse prevention in schizophrenia: a systematic review and meta-analysis. Lancet 379:2063–2071

Article  CAS  PubMed  Google Scholar 

Luvsannyam E, Jain MS, Pormento MKL, Siddiqui H, Balagtas ARA, Emuze BO, Poprawski T (2022) Neurobiology of Schizophrenia: A Comprehensive Review. Cureus 14(4):e23959

PubMed  PubMed Central  Google Scholar 

Carbon M, Correll CU (2014) Clinical predictors of therapeutic response to antipsychotics in schizophrenia. Dialogues Clin Neurosci 16:505–524

Article  PubMed  PubMed Central  Google Scholar 

Emsley R, Chiliza B, Asmal L, Harvey BH (2013) The nature of relapse in schizophrenia. BMC Psychiatry 13:50

Article  PubMed  PubMed Central  Google Scholar 

Correll CU, Martin A, Patel C et al (2022) Systematic literature review of schizophrenia clinical practice guidelines on acute and maintenance management with antipsychotics. Schizophr 8:5

Article  Google Scholar 

Hartung D, Low A, Jindai K, Mansoor D, Judge M, Mendelson A, Kansagara D, Motu M, Freeman M, Kondo K (2017) Interventions to improve pharmacological adherence among adults with psychotic spectrum disorders and bipolar disorder: a systematic review. Psychosomatics 58:101–112

Article  PubMed  Google Scholar 

Mibel FHE, Mari L (2013) Non-compliance to medication in psychiatric patients, vol 2013. Tuku University of Applied Sciences, Turku

Google Scholar 

Cramer JA, Rosenheck R (1998) Compliance with medication regimens for mental and physical disorders. Psychiatr Serv 49:196–201

Article  CAS  PubMed  Google Scholar 

Colom F, Lam D (2005) Psychoeducation: Improving outcomes in bipolar disorder. Eur Psychiatry 5–6:359–364

Article  Google Scholar 

National Institute for Health and Care Excellence (2020) Therapeutic education programmes in mental health. NICE, London

Google Scholar 

WHO (2013) Mental Health Action Plan 2013–2020. World Health Organization, Geneva

Google Scholar 

Sendt K-V, Tracy DK, Bhattacharyya S (2015) A systematic review of factors influencing adherence to antipsychotic medication in schizophrenia-spectrum disorders. Psychiatry Res 225:14–30

Article  PubMed  Google Scholar 

Xiao J, Mi W, Li L, Shi Y, Zhang H (2015) High relapse rate and poor medication adherence in the Chinese population with schizophrenia: Results from an observational survey in the People’s Republic of China. Neuropsychiatr Dis Treat 11:1161–1167

PubMed  PubMed Central  Google Scholar 

Yoshida K, Müller DJ (2020) Pharmacogenetics of antipsychotic drug treatment: update and clinical implications. Mol Neuropsychiatry 5(Suppl 1):1–26

PubMed  Google Scholar 

Pouget JG, Shams TA, Tiwari AK, Müller DJ (2014) Pharmacogenetics and outcome with antipsychotic drugs. Dialogues Clin Neurosci 16(4):555–566

Article  PubMed  PubMed Central  Google Scholar 

Murphy LE, Fonseka TM, Bousman CA, Müller DJ (2022) Gene-drug pairings for antidepressants and antipsychotics: level of evidence and clinical application. Mol Psychiatry 27(1):593–605

Article  CAS  PubMed  Google Scholar 

Virelli CR, Mohiuddin AG, Kennedy JL (2021) Barriers to clinical adoption of pharmacogenomic testing in psychiatry: a critical analysis. Transl Psychiatry 11(1):509

Article  PubMed  PubMed Central  Google Scholar 

Saadullah Khani N, Hudson G, Mills G, Ramesh S, Varney L, Cotic M, Abidoph R, Richards-Belle A, Carrascal-Laso L, Franco-Martin M, Kaas-Hansen BS, Jürgens G, Barrett B, Jin H, Bramon E (2024) A systematic review of pharmacogenetic testing to guide antipsychotic treatment. Nat Ment Health 2(5):616–626

Article  PubMed  PubMed Central  Google Scholar 

Swen JJ, van der Wouden CH, Manson LE, Abdullah-Koolmees H, Blagec K, Dupui M, Guchelaar HJ (2023) Pharmacogenetics in psychiatry: The Dutch Pharmacogenetics Working Group guideline for CYP2D6 and CYP2C19 in antipsychotic use. Clin Pharmacol Ther 114(3):662–672. https://doi.org/10.1002/cpt.2921

Article  Google Scholar 

Paulzen M, Haen E, Stegmann B, Hiemke C, Gründer G, Lammertz SE, Schoretsanitis G (2022) CYP2D6-guided risperidone treatment in schizophrenia: A randomized controlled trial demonstrating reduced extrapyramidal symptoms. Pharmacopsychiatry 55(4):199–206. https://doi.org/10.1055/a-1791-7263

Article  Google Scholar 

Bousman CA, Bengesser SA, Aitchison KJ, Amare AT, Aschauer H, Baune BT, … Zomorrodi-Milani S (2021) Review and consensus on pharmacogenomic testing in psychiatry: Focus on major depressive disorder, bipolar disorder, and schizophrenia. Front Pharmacol 12:724791. https://doi.org/10.3389/fphar.2021.724791

Mizuno Y, Suzuki T, Nakajima S, Uchida H, Takeuchi H, Mimura M (2022) Clinical implementation of CYP2D6 genotyping for risperidone in Japanese patients with schizophrenia: A prospective, randomized controlled trial. Neuropsychopharmacology Reports 42(1):78–85. https://doi.org/10.1002/npr2.12268

Article  CAS  Google Scholar 

Zhang X, Li J, Wang L, Liu Z, Hu Y, Fang Y, … Yu X (2023) CYP1A2 polymorphisms and therapeutic drug monitoring-guided clozapine dosing in Han Chinese schizophrenia patients: A multicenter cohort study. Asian J Psychiatr 79:103456. https://doi.org/10.1016/j.ajp.2022.103456

Saiz-Rodríguez M, Ochoa D, Belmonte C, Román M, Vieira de Lara D, Zubiaur P et al (2019) Polymorphisms in CYP1A2, CYP2C9 and ABCB1 affect agomelatine pharmacokinetics. J Psychopharmacol 33:522–531

Article  PubMed  Google Scholar 

Jeleń AM, Sałagacka A, Żebrowska MK, Mirowski M, Talarowska M, Gałecki P et al (2015) The influence of C3435T polymorphism of the ABCB1 gene on genetic susceptibility to depression and treatment response in polish population-preliminary report. Int J Med Sci 12:974–979

Article  PubMed  PubMed Central  Google Scholar 

Hall-Flavin DK, Winner JG, Allen JD, Carhart JM, Proctor B, Snyder KA et al (2013) Utility of integrated pharmacogenomic testing to support the treatment of major depressive disorder in a psychiatric outpatient setting. Pharmacogenet Genomics 23:535–548

Article  CAS  PubMed  Google Scholar 

Benner JS, Glynn RJ, Mogun H, Neumann PJ, Weinstein MC, Avorn J et al (2002) Long-term persistence in use of statin therapy in elderly patients. JAMA 288:455

Article  PubMed  Google Scholar 

Christian C, Borden BA, Danahey K, Yeo K-TJ, van Wijk XMR, Ratain MJ et al (2020) Pharmacogenomic-based decision-support to predict adherence to medications. Clin Pharmacol Ther 108:368–376

Article  CAS  PubMed  Google Scholar 

Jürgens G, Andersen SE, Rasmussen HB et al (2020) Effect of routine cytochrome P450 2D6 and 2C19 genotyping on antipsychotic drug persistence in patients with schizophrenia: a randomized clinical trial. JAMA Netw Open 3(12):e2027909

Article  PubMed  Google Scholar 

Walden LM, Brandl EJ, Tiwari AK et al (2019) Genetic testing for CYP2D6 and CYP2C19 suggests improved outcome for antidepressant and antipsychotic medication. Psychiatry Res 279:111–115

Article  CAS  PubMed  Google Scholar 

Wang H, Chen Y, Lv J, Cheng X, Cao Q, Wang D, Zhang L et al (2024) Bilateral gene therapy in children with autosomal recessive deafness 9: single-arm trial results. Nat Med 30:1898–1904. https://doi.org/10.1038/s41591-024-03023-5

Article  CAS